Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonca-R Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
NCT05600686Phase 2Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by University of California, Davis. Primary endpoint: Complete Response Rate. Started May 2023; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05600686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600686.